Smarter cancer care
Exact Sciences brings the promise of precision medicine to life with Oncotype DX®, a full suite of genomic tests.
LEARN MORE
Deborah, an Oncotype DX patient

ASCO Guidelines 2022

Updated ASCO Guidelines strongly recommend use of the Oncotype DX Breast Recurrence Score® Test in node-negative and the majority of node-positive early-stage breast cancer patients. 
ASCO is a trademark of the American Society of Clinical Oncology. 
ASCO does not endorse any product or therapy.

Landmark RxPONDER Trial Results

Publication in The New England Journal of Medicine confirms that tens of thousands of women with node-positive, early-stage breast cancer can avoid chemotherapy with the Oncotype DX® test
Improving Patient Outcomes
Copyright © 2004- Genomic Health, Inc., an Exact Sciences corporation. All Rights Reserved.
In the US and certain other jurisdictions, Genomic Health, Oncotype DX, Oncotype IQ, Recurrence Score, Oncotype DX Breast Recurrence Score, Oncotype DX Colon Recurrence Score, Oncotype DX Genomic Prostate Score, and Oncotype DX AR-V7 Nucleus Detect are registered trademarks, and "Making cancer care smarter" and GPS are pending registered trademarks, of Genomic Health, Inc., an Exact Sciences corporation.
Making cancer care smarter.™